A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Clinical trial NCT04344158 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04344158
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-11
- Primary completion
- 2026-12-01
- Enrollment
- 648
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.